drugset

drugset / Trial / NCT00841217

Regulation of Lipoprotein Transport in Metabolic Syndrome

NCT00841217 ↗

Phase 4 Completed 13 enrolled The University of Western Australia National Heart Foundation, Australia · collab

RandomizedCrossoverTriple-blindTreatment

Summary

The purpose of this study is to determine whether PPAR-delta agonist (GW5015156)had favorable effect on lipoprotein metabolism.

Timeline

Start: 2003-04
Primary completion: 2005-08
Completion: 2008-12

Publications

Ooi EM, Watts GF, Sprecher DL, Chan DC, Barrett PH. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity. J Clin Endocrinol Metab. 2011 Oct;96(10):E1568-76. doi: 10.1210/jc.2011-1131. Epub 2011 Aug 3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	GW501516	Small molecule	2.5 mg	—

Indications